ACY-1083 |
| Katalog-Nr.GC34458 |
ACY-1083 ist ein selektiver und gehirngängiger HDAC6-Inhibitor mit einer IC50 von 3 nM und ist 260-fach selektiver für HDAC6 als alle anderen Klassen von HDAC-Isoformen. ACY-1083 kehrt die durch Chemotherapie verursachte periphere Neuropathie effektiv um.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1708113-43-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ACY-1083 is a selective and brain-penetrating HDAC6 inhibitor with an IC50 of 3 nM and is 260-fold more selective for HDAC6 than all other classes of HDAC isoforms. ACY-1083 effectively reverses chemotherapy-induced peripheral neuropathy[1]. HDAC6|3 nM (IC50)
[1]. Krukowski K, et al. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain. 2017 Jun;158(6):1126-1137.
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *